
The Rx Recap: March 8-13
Key Takeaways
- Genomic profiling with the Aida test may identify HR-positive/HER2-negative early breast cancer subsets unlikely to benefit from adjuvant radiotherapy after breast-conserving surgery.
- Biosimilar developers are restructuring to capture forthcoming patent cliffs, while FDA complete response letters and regional market dynamics continue to shape adoption trajectories.
This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.
Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.
New Test Predicts Breast Cancer Recurrence and Radiation Therapy Benefit
A study reported by
Global Biosimilar Market Sees Structural Shifts, Regulatory Hurdles, and Pipeline Gains
Reported by
The Hidden Infection Risk Hospitals Keep Missing: Shared Equipment Without Ownership
An article from
How the Small Details Shape Euthanasia for Clients and Care Teams
Reported by
Anticipating Care: Proactive Consultation-Liaison Psychiatry
An article in
Want to read more on specialty care, pharmacy, industry sciences, and more? Check out
Related to this article








